Circulating Immune Complexes in 50-Year-Old Men as a Strong and Independent Risk Factor for Myocardial Infarction

Background—Circulating immune complexes (CICs) and autoantibodies against oxidatively modified LDLs (oxLDLs) and cardiolipin occur in patients with atherosclerosis and myocardial infarction (MI). The ability of such CICs and antibodies to predict myocardial infarction (MI) was investigated in a prospective nested case-control study in which healthy 50-year-old men were followed for 20 years. Methods and Results—Two hundred fifty-seven men were included in the study, and 119 developed MI (39 died) between 50 and 70 years of age. One hundred thirty-eight randomly chosen men who did not develop MI up to 70 years of age served as controls. The prevalence of elevated levels of CICs and the concentration of CICs in men who developed MI were higher than in those who remained healthy. The concentration of CICs at age 50 was associated with a marked increased risk for MI, and this risk was independent of other conventionally recognized risk factors. There was a positive correlation between the levels of CIC and IgG antibodies to cardiolipin in men who developed MI. The level of IgG antibodies and the prevalence of elevated IgG and IgM antibodies to cardiolipin were higher in those who developed MI and had CICs than in those without CICs. Among men homozygous for C4 null alleles, those who developed MI had higher concentrations of CICs than did those who remained healthy. Conclusions—This prospective study shows that CICs alone or in combination with autoantibodies against cardiolipin in healthy males at 50 years of age predict subsequent MI between the age of and 70 years.

[1]  A. Lefvert.  Heterogeneity of autoantibodies against cardiolipin and oxidatively modified LDLs revealed by human monoclonal antibodies , 2000, Journal of internal medicine.

[2]  A. Hamsten,et al.  C 4 null alleles and myocardial infarction/SUB , 1999 .

[3]  A. Hamsten,et al.  C4 null alleles and myocardial infarction. , 1999, Atherosclerosis.

[4]  R W Evans,et al.  Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. , 1999, Clinical immunology.

[5]  K. Brismar,et al.  Anti‐cardiolipin antibodies and circulating immune complexes in type 1 diabetes mellitus: increased prevalence and relation to vascular complications , 1999, Clinical and experimental immunology.

[6]  V. Tertov,et al.  Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification. , 1998, Atherosclerosis.

[7]  L. Berglund,et al.  Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Lefvert,et al.  Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti‐phospholipid syndrome (APLS) , 1997, Clinical and experimental immunology.

[9]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[10]  M. Ohrvall,et al.  The serum cholesterol ester fatty acid composition but not the serum concentration of alpha tocopherol predicts the development of myocardial infarction in 50-year-old men: 19 years follow-up. , 1996, Atherosclerosis.

[11]  V. Tertov,et al.  Characteristics of low density lipoprotein isolated from circulating immune complexes. , 1996, Atherosclerosis.

[12]  M. Lopes-Virella,et al.  Isolation and characterization of human antioxidized LDL autoantibodies. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[13]  A. Lefvert,et al.  Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL , 1995, Clinical and experimental immunology.

[14]  G. Siest,et al.  Cholesterol content of circulating immune complexes in patients with coronary stenosis and subjects without evidence of atherosclerosis. , 1995, Clinical chemistry.

[15]  A. Hamsten,et al.  Association between circulating immune complexes, complement C4 null alleles, and myocardial infarction before age 45 years. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[16]  U. de Faire,et al.  Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[17]  L. Tenkanen,et al.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. , 1995, Circulation.

[18]  V. Tertov,et al.  Autoantibodies against low-density lipoprotein and atherogenic potential of blood. , 1993, Annals of medicine.

[19]  M. Fishbein,et al.  Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[20]  V. Tertov,et al.  Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. , 1992, Circulation research.

[21]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[22]  Alexander N. Orekhov,et al.  Lipoprotein immune complexes and their role in atherogenesis , 1991 .

[23]  K. Shunk,et al.  Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  P. Libby,et al.  Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[25]  M. Nieminen,et al.  Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. , 1990, Microbial pathogenesis.

[26]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[27]  H. A. Kahn,et al.  Statistical Methods in Epidemiology , 1989 .

[28]  P. Venables,et al.  Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. , 1989, Annals of the rheumatic diseases.

[29]  M. Lopes-Virella,et al.  Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation , 1988, The Journal of experimental medicine.

[30]  M. Haberland,et al.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.

[31]  G. Hauptmann,et al.  Inherited deficiency of the fourth component of human complement. , 1988, Immunodeficiency reviews.

[32]  P. Kay,et al.  C4 allotyping on plasma or serum: application to routine laboratories. , 1988, Human immunology.

[33]  G. Hughes,et al.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. , 1987, Clinical and experimental immunology.

[34]  J. Schifferli,et al.  The role of complement and its receptor in the elimination of immune complexes. , 1986, The New England journal of medicine.

[35]  C. Steffen,et al.  [Immune complexes in myocardial infarct]. , 1986, Wiener klinische Wochenschrift.

[36]  A. Hamsten,et al.  ANTIBODIES TO CARDIOLIPIN IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION: AN ASSOCIATION WITH RECURRENT CARDIOVASCULAR EVENTS , 1986, The Lancet.

[37]  A. G. Vinogradov,et al.  Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation. , 1985, Atherosclerosis.

[38]  H. Lithell,et al.  Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study. , 1985, Atherosclerosis.

[39]  Smith Gw,et al.  Circulating immune complexes in myocardial infarction. , 1983 .

[40]  B. Olaisen,et al.  Statement on the nomenclature of human C4 allotypes. , 1983, Immunobiology.

[41]  G. Smith,et al.  Circulating immune complexes in myocardial infarction. , 1983, Journal of clinical & laboratory immunology.

[42]  G. Striker,et al.  The disappearance kinetics and glomerular deposition of small-latticed soluble immune complexes. , 1982, Immunology.

[43]  C. Alper,et al.  Inherited polymorphism of human C4 as revealed by desialyzation. , 1980, Immunobiology.

[44]  G. Füst,et al.  Studies on the occurrence of circulating immune complexes in vascular diseases. , 1978, Atherosclerosis.

[45]  T. Lundman,et al.  A Survey for Circulating Immune Complexes in Patients with Acute Myocardial Infarction , 1977, Scandinavian journal of immunology.

[46]  E. Donoso,et al.  Myocardial infarction due to coronary atherosclerosis in three young adults with systemic lupus erythematosus. , 1975, The American journal of cardiology.

[47]  R. Gabriel,et al.  Soluble-complex formation after myocardial infarction. , 1974, Lancet.

[48]  W. Arend,et al.  Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation. , 1971 .

[49]  J. Miller,et al.  Thymus and Antigen‐Reactive Cells , 1969, Transplantation reviews.

[50]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.